3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 49%
As Asian markets navigate a period of volatility influenced by global tech stock fluctuations and geopolitical tensions, investors are increasingly on the lookout for opportunities that may be undervalued amidst the broader market shifts. In this environment, identifying stocks trading at significant discounts can offer potential value, especially when considering companies with strong fundamentals and resilience in challenging economic landscapes.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Techwing (KOSDAQ:A089030) | ₩46200.00 | ₩91323.51 | 49.4% |
| SHIFT (TSE:3697) | ¥766.50 | ¥1490.88 | 48.6% |
| Samyang Foods (KOSE:A003230) | ₩1109000.00 | ₩2214803.55 | 49.9% |
| Pan-United (SGX:P52) | SGD1.59 | SGD3.16 | 49.7% |
| OVERLAP HoldingsInc (TSE:414A) | ¥855.00 | ¥1664.58 | 48.6% |
| Moshi Moshi Retail Corporation (SET:MOSHI) | THB38.75 | THB76.04 | 49% |
| Info-Tech Systems (SGX:ITS) | SGD0.98 | SGD1.94 | 49.4% |
| Horizon Robotics (SEHK:9660) | HK$4.75 | HK$9.36 | 49.2% |
| Hana Technology (KOSDAQ:A299030) | ₩11750.00 | ₩23288.61 | 49.5% |
| Anhui Tongguan Copper Foil Group (SZSE:301217) | CN¥95.36 | CN¥187.20 | 49.1% |
Let's review some notable picks from our screened stocks.
MicroTech Medical (Hangzhou) (SEHK:2235)
Overview: MicroTech Medical (Hangzhou) Co., Ltd. specializes in providing diabetes management, treatment, and monitoring medical devices both in China and internationally, with a market cap of HK$2.96 billion.
Operations: The company generates revenue of CN¥660.79 million from its research, development, manufacturing, and sales of medical devices focused on diabetes management and treatment.
Estimated Discount To Fair Value: 37.4%
MicroTech Medical (Hangzhou) is trading at HK$7.11, significantly below its estimated future cash flow value of HK$11.35, suggesting it may be undervalued based on cash flows. The company's earnings are forecast to grow substantially at 44.9% annually, outpacing the Hong Kong market's growth rate. Recent marketing approval for its LinX Continuous Glucose Monitoring System in South Korea enhances its market access and revenue potential in East Asia, while a share repurchase program aims to boost net asset value and earnings per share.
- Our earnings growth report unveils the potential for significant increases in MicroTech Medical (Hangzhou)'s future results.
- Click to explore a detailed breakdown of our findings in MicroTech Medical (Hangzhou)'s balance sheet health report.
Moshi Moshi Retail Corporation (SET:MOSHI)
Overview: Moshi Moshi Retail Corporation Public Company Limited operates in Thailand, focusing on the retail and wholesale of lifestyle products, with a market capitalization of THB12.79 billion.
Operations: The company's revenue is primarily derived from its retail segment, which accounts for THB3.36 billion, supplemented by a wholesale segment generating THB452.46 million.
Estimated Discount To Fair Value: 49%
Moshi Moshi Retail Corporation, trading at THB38.75, is priced significantly below its estimated future cash flow value of THB76.04, indicating potential undervaluation. The company's earnings are projected to grow 13.8% annually, surpassing the Thai market's growth rate of 9.9%. Recent first-quarter results showed revenue increased to THB988.34 million from THB843.23 million year-over-year, alongside a rise in net income to THB190.99 million from THB156.02 million previously reported.
- Our expertly prepared growth report on Moshi Moshi Retail Corporation implies its future financial outlook may be stronger than recent results.
- Click here to discover the nuances of Moshi Moshi Retail Corporation with our detailed financial health report.
Zhejiang Meili High Technology (SZSE:300611)
Overview: Zhejiang Meili High Technology Co., Ltd. is involved in the research, development, production, and sale of high-end spring products both in China and internationally, with a market cap of CN¥5.22 billion.
Operations: Zhejiang Meili High Technology Co., Ltd. generates revenue through its research, development, production, and sale of high-end spring products domestically and abroad.
Estimated Discount To Fair Value: 37.4%
Zhejiang Meili High Technology, trading at CNY 24.71, is valued below its projected future cash flow of CNY 39.49. Despite a recent dip in net income to CNY 17.32 million for Q1 2026, the company anticipates robust earnings growth of over 20% annually for the next three years, outpacing the Chinese market's average. A share buyback plan worth up to CNY 70 million further underscores its strategic financial maneuvers amidst an unstable dividend history.
- The analysis detailed in our Zhejiang Meili High Technology growth report hints at robust future financial performance.
- Click here and access our complete balance sheet health report to understand the dynamics of Zhejiang Meili High Technology.
Next Steps
- Navigate through the entire inventory of 215 Undervalued Asian Stocks Based On Cash Flows here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com